FibroGen 향후 성장

Future 기준 점검 0/6

FibroGen 의 수익과 수익은 각각 연간 8.5% 및 2.8% 감소할 것으로 예상됩니다 while EPS는 연간 9.5% 만큼 성장할 것으로 예상됩니다.

핵심 정보

-2.8%

이익 성장률

9.52%

EPS 성장률

Biotechs 이익 성장	23.2%
매출 성장률	-8.5%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	11 Nov 2025

최근 향후 성장 업데이트

Recent updates

Is FibroGen (NASDAQ:FGEN) A Risky Investment?

Dec 16

Simplifying Operations And Advancing FG-3246 Will Secure Future Success

Apr 10 Strategic cost reductions and the sale of FibroGen China enhance financial stability, extending cash runway and potentially boosting overall financial performance.

Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26%

Apr 08

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 46% Share Price Rise

Feb 21

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise

Dec 25

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

Oct 29

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

Aug 19

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

Jul 04

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13

이익 및 매출 성장 예측

NasdaqGS:FGEN - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	6	-54	N/A	N/A	1
12/31/2027	6	-52	N/A	N/A	2
12/31/2026	6	-54	N/A	N/A	2
12/31/2025	7	-46	N/A	N/A	2
9/30/2025	8	-52	-17	-17	N/A
6/30/2025	7	-87	-24	-23	N/A
3/31/2025	7	-121	-76	-76	N/A
12/31/2024	30	-153	-138	-138	N/A
9/30/2024	-47	-239	-126	-126	N/A
6/30/2024	-7	-255	-203	-202	N/A
3/31/2024	36	-295	-275	-273	N/A
12/31/2023	47	-323	-318	-315	N/A
9/30/2023	155	-294	-352	-349	N/A
6/30/2023	131	-322	-319	-317	N/A
3/31/2023	116	-307	-242	-239	N/A
12/31/2022	141	-294	-185	-146	N/A
9/30/2022	123	-362	-188	-148	N/A
6/30/2022	263	-220	-118	-52	N/A
3/31/2022	258	-281	-112	-46	N/A
12/31/2021	235	-290	-112	-82	N/A
9/30/2021	284	-215	-66	-34	N/A
6/30/2021	172	-231	-85	-80	N/A
3/31/2021	190	-183	92	96	N/A
12/31/2020	176	-189	78	82	N/A
9/30/2020	119	-229	40	44	N/A
6/30/2020	108	-311	13	18	N/A
3/31/2020	257	-110	-166	-161	N/A
12/31/2019	257	-77	-84	-79	N/A
9/30/2019	357	42	-58	-51	N/A
6/30/2019	353	49	N/A	-15	N/A
3/31/2019	205	-90	N/A	-22	N/A
12/31/2018	213	-86	N/A	-76	N/A
9/30/2018	136	-141	N/A	-60	N/A
6/30/2018	147	-123	N/A	-87	N/A
3/31/2018	133	-132	N/A	-71	N/A
12/31/2017	131	-121	N/A	-67	N/A
9/30/2017	132	-121	N/A	-84	N/A
6/30/2017	122	-121	N/A	-67	N/A
3/31/2017	181	-64	N/A	-3	N/A
12/31/2016	183	-58	N/A	7	N/A
9/30/2016	172	-79	N/A	-14	N/A
6/30/2016	162	-100	N/A	-50	N/A
3/31/2016	193	-67	N/A	6	N/A
12/31/2015	181	-86	N/A	-19	N/A
9/30/2015	172	-85	N/A	-3	N/A
6/30/2015	167	-79	N/A	4	N/A
3/31/2015	136	-98	N/A	-4	N/A

애널리스트 향후 성장 전망

수입 대 저축률: FGEN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: FGEN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: FGEN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: FGEN 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -8.5%).

고성장 매출: FGEN 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -8.5%).

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: FGEN의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/02 22:50
종가	2026/01/02 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

FibroGen, Inc.는 13명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Jason Matthew Gerberry	BofA Global Research
Matthew Keller	H.C. Wainwright & Co.
Xiaodong Zhang	H.C. Wainwright & Co.

FibroGen 향후 성장

Future 기준 점검 0/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates fall by 10%

Consensus revenue estimates fall by 30%

Consensus revenue estimates decrease by 42%

Consensus estimates of losses per share improve by 17%

Price target decreased by 17% to US$10.38

Consensus revenue estimates decrease by 13%, EPS upgraded

Recent updates

Is FibroGen (NASDAQ:FGEN) A Risky Investment?

Consensus EPS estimates fall by 10%

Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

FibroGen, Inc. to Report Q3, 2025 Results on Nov 10, 2025

FibroGen, Inc. Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates fall by 30%

Second quarter 2025 earnings: EPS and revenues miss analyst expectations

FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes

FibroGen, Inc. to Report Q2, 2025 Results on Aug 11, 2025

New major risk - Revenue and earnings growth

Independent Chairman of the Board recently bought US$119k worth of stock

FibroGen, Inc. Announces the Appointment of Michael Kauffman to Its Board of Directors, Effective June 4, 2025

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. to Report Q1, 2025 Results on May 12, 2025

FibroGen, Inc., Annual General Meeting, Jun 04, 2025

Simplifying Operations And Advancing FG-3246 Will Secure Future Success

Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 26%

Fibrogen, Inc. Announces Publication of Results from Phase 1 Monotherapy Study of Fg-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology

Independent Chairman of the Board recently bought US$105k worth of stock

Consensus revenue estimates decrease by 42%

Full year 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. to Report Q4, 2024 Results on Mar 17, 2025

FibroGen, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

FibroGen, Inc. Announces Cessation of Christine L. Chung as Senior Vice President, China Operations

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 46% Share Price Rise

New major risk - Share price stability

AstraZeneca PLC (LSE:AZN) agreed to acquire Beijing Fibrogen Medical Technology Development Co., Ltd. from FibroGen, Inc. (NasdaqGS:FGEN).

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise

FibroGen, Inc. Appoints David DeLucia as Chief Financial Officer

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

FibroGen Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies

Consensus estimates of losses per share improve by 17%

FibroGen, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 3000 Index

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting

Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals Announce Settlement with FibroGen, Inc

Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

CEO & Director recently bought US$95k worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

Full year 2023 earnings: EPS and revenues miss analyst expectations

FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

New major risk - Financial position

FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Now 25% undervalued after recent price drop

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Now 30% undervalued after recent price drop

New minor risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 17% to US$10.38

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer